Defining Oligometastatic Disease in the New Era of PSMA-PET Imaging for Primary Staging of Prostate Cancer
Open Access
Abstract
Oligometastatic prostate cancer has traditionally been defined in the literature as a limited number of metastatic lesions (either to soft tissue or bone), typically based on findings seen on CT, MRI, and skeletal scintigraphy. Although definitions have varied among research studies, many important clinical trials have documented effective treatments and prognostication in patients with oligometastatic prostate cancer. In current clinical practice, prostate-specific membrane antigen (PSMA)-PET/CT is increasingly utilized for the initial staging of high-risk patients and, in many cases, detecting metastases that would have otherwise been undetected with conventional staging imaging. Thus, patients with presumed localized and/or oligometastatic prostate cancer undergo stage migration based on more novel molecular imaging. As a result, it is challenging to apply the data from the era before widespread PET utilization to current clinical practice and to relate current trials using PSMA-PET/CT for disease detection to older studies using conventional staging imaging alone. This manuscript aims to review the definition of oligometastatic prostate cancer, summarize important studies utilizing both PSMA-PET/CT and conventional anatomic imaging, discuss the concept of stage migration, and discuss current problems and challenges with the current definition of oligometastatic disease.Keywords
This publication has 52 references indexed in Scilit:
- The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic CarcinomaAmerican Journal of Surgical Pathology, 2016
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate CancerNew England Journal of Medicine, 2015
- Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate CancerMolecular Imaging and Biology, 2015
- PET/CT imaging and the oligometastatic prostate cancer patient: an opportunity for a curative approach with high-dose radiotherapy?European Journal of Nuclear Medicine and Molecular Imaging, 2014
- Localized Prostate Cancer Detection with18F FACBC PET/CT: Comparison with MR Imaging and Histopathologic AnalysisRadiology, 2014
- Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastasesActa Oncologica, 2013
- 11C-Choline PET/CT in the diagnosis of primary prostate cancer. Impact on treatment planningMédecine Nucléaire, 2013
- PSMA as a target for radiolabelled small moleculesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2013
- Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitationsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2013
- 11C-Choline Positron Emission Tomography in Prostate Cancer: Primary Staging and Recurrent Site StagingUrologia Internationalis, 2005